H. pylori eradication therapy helpful for controlling functional dyspepsia: Study

Leeds, UK: High-quality evidence suggests that Helicobacter pylori eradication therapy both cures and improves symptoms of functional dyspepsia (FD), although the benefit is modest, reveals a recent study. The study appears in the BMJ journal Gut. 

Functional dyspepsia (FD) is a chronic disorder that is not easy to treat. H. pylori may be a contributor to its pathophysiology. A Cochrane review performed in 2006 had suggested that eradication therapy is beneficial, but since then numerous randomized controlled trials (RCTs) have been published. Alexander C Ford, Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK, and colleagues, therefore, aimed to evaluate the impact of eradication therapy on both cure and improvement of FD, as well as whether any benefit was likely to arise from the eradication of H. pylori.

For this purpose, the researchers searched the medical literature through October 2021 to identify RCTs examining the efficacy of eradication therapy in H. pylori-positive adults with FD. Those in the control group received antisecretory therapy or prokinetics, with or without placebo antibiotics, or placebo alone. Follow-up was for ≥3 months.

Dichotomous data were pooled to obtain a relative risk (RR) of symptoms not being cured or symptoms not improving. Also, the number needed to treat (NNT) was estimated. 

Twenty-nine RCTs recruited 6781 H. pylori-positive patients with FD. 

To conclude, there is high quality evidence to suggest that H. pylori eradication therapy leads to both cure and improvement in FD symptoms, although the benefit is modest.

Reference:

Ford AC, Tsipotis E, Yuan Y, et alEfficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysisGut Published Online First: 12 January 2022. doi: 10.1136/gutjnl-2021-326583